Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Rhône-Poulenc Rorer

RPR's presentation of data from its Phase III trial of

Rilutek

(riluzole) to treat amyotrophic lateral sclerosis met with a mixed reception at the American Academy of Neurology meeting, according to Cowen's Lonergan (see Clinical

Read the full 372 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE